Prosecution Insights
Last updated: November 04, 2026
Application No. 17/611,829

COMPOSITIONS AND METHODS FOR IMPROVING TREATMENT OUTCOMES FOR PATIENTS HAVING HEMATOLOGICAL MALIGNANCIES USING AN EXPANDED STEM CELL PRODUCT

Final Rejection §103§112
Filed
Nov 07, 2022
Priority
May 17, 2019 — provisional 62/849,588 +2 more
Examiner
BELYAVSKYI, MICHAIL A
Art Unit
1644
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Deverra Therapeutics Inc.
OA Round
2 (Final)
64%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
718 granted / 1122 resolved
+4.0% vs TC avg
Strong +28% interview lift
Without
With
+28.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
44 currently pending
Career history
1204
Total Applications
across all art units

Statute-Specific Performance

§101
3.6%
-36.4% vs TC avg
§103
31.3%
-8.7% vs TC avg
§102
14.9%
-25.1% vs TC avg
§112
19.7%
-20.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1122 resolved cases

Office Action

§103 §112
RESPONSE TO APPLICANT’S AMENDMENT 1. Applicants amendment filed on 08/19/26 is acknowledged. 2. Claims 1-3,7,11,12,14,16,25-28,32-34,38,39,40,42,44 are pending. 3. Claims 1-3,7,11,12,14,16 stand withdrawn from further consideration by the Examiner, 37 C.F.R. § 1.142(b) as being drawn to nonelected inventions. Claims 25-28,32-34,38,39,40,42,44 read on a method of improving treatment outcome for human patient having hematological malignancy are under consideration in the instant application. The following new ground of rejection is necessitated by the amendment filed on 08/19/26. 4. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. 5. Claims 25-28,32-34,38,39,40,42,44 are rejected under 35 U.S.C. 103 as being unpatentable over US Patent Application 20130095079 and US Patent Application 20110230422 in view of newly cited US Patent Application 20210223248. Applicant’s arguments filed on 08/19/26 have been fully considered but have not been found convincing. Applicant asserts that US Patent Application’079 teaches that the dose of administered expanded hematopoietic stem cells based on the weight of the patient. The instant claims recited administering of a fixed dose of hematopoietic stem cells. It is noted that the instant specification defined “fixed dose” as 50-400 x 106 cells ( see paragraph 0011 of the instant Specification in particular). US Patent Application’079 explicitly teaches that the dose of administered hematopoietic stem cells is 106 cells/kg ( see paragraph 0358 in particular). If the average weight of the human patient between 60-100 kg, it would mean that to total amount of administered hematopoietic stem cells would be 60-100 x 106 cells. Thus, it is the Examiner’s position that the claimed dose of administered “fixed dose” of hematopoietic stem cells is an obvious variation of the recited in US Patent Application’079 dose of administered hematopoietic stem cells. As has been stated previously, US Patent Application ‘079 teaches a method of treating hematological malignancy in a patient comprising administering to the patient chemotherapy regimen and administering an expanded hematopoietic stem cells ( see entire document, paragraphs 0004, 0017, 0036, 0043, 0060, 0067, 0189 in particular) in particular). US Patent Application ‘079 teaches a step of determining effectivity of the claimed method that is obviously comprising a step of monitoring the status of the patient to determine whether the patient has achieved a remission. Since US Patent Application ‘079 teaches does not explicitly teach that administered hematopoietic stem cells should be matching for HLA type of the donor, it would be immediately obvious to one skill in the art that US Patent Application ‘079 teaches said expanded hematopoietic stem cells are selected without matching to the HLA type. US Patent Application ‘422 teaches a method of treating hematological malignancy in a patient comprising administering to the patient chemotherapy regimen and administering an expanded hematopoietic stem cells ( see entire document, paragraphs 0012, 0014, 0017, 0020-0022 in particular). US Patent Application ‘422 teaches a step of determining effectivity of the claimed method that is obviously comprising a step of monitoring the status of the patient to determine whether the patient has achieved a remission. Since US Patent Application ‘422 teaches does not explicitly teach that administered hematopoietic stem cells should be matching for HLA type of the donor, it would be immediately obvious to one skill in the art that US Patent Application ‘079 teaches said expanded hematopoietic stem cells are selected without matching to the HLA type. All the claimed elements were known in the prior art and one skill in the art could have combine the elements as claimed by known methods with no change in their respective function and the combination would have yield predictable results to one of ordinary skill in the art at the time of the invention ( see KSR International Co v Teleflex Inc., 550U.S.-, 82 USPQ2d 1385, 2007). It is noted that US Patent Application ‘079 and US Patent Application ‘422 do not explicitly teach the use of second chemotherapy regime. Newly cited US Patent Application ‘248 teaches that is certain embodiments a second chemotherapy regiment may be used in the method of treating patient having hematological malignancy to reduce the risk of relapse( see entire document, paragraphs 0038, 0050, 0129, 0130, 0134 in particular). All the claimed elements were known in the prior art and one skill in the art could have combine the elements as claimed by known methods with no change in their respective function and the combination would have yield predictable results to one of ordinary skill in the art at the time of the invention ( see KSR International Co v Teleflex Inc., 550U.S.-, 82 USPQ2d 1385, 2007). Thus it would have been to one of ordinary skill in the art before the effective filing date of the claimed invention to use the second chemotherapy regiment in the method of treating hematological malignancy taught by US Patent Application ‘079 and US Patent Application ‘422 with a reasonable expectation of success because the prior art suggests that a second chemotherapy regiment reduce the risk of relapse. Claims 26-28, 33,34,38,39, 40,42 are included because it would be conventional and within the skill of the art to : (i) identify an optimal timing and dosage of administering stem cells; (ii) type of hematological malignancy to be treated,; (iii) optimal chemotherapy regime; Further, it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. In re Aller, 220 F2d 454,456,105 USPQ 233; 235 (CCPA 1955). see MPEP § 2144.05 part II A. It is well settled that "discovery of an optimum value of a result effective variable in a known process is ordinarily within the skill of the art." In re Boesch, 617 F.2d 272, 276, 205 USPQ 215, 219 (CCPA 1980). See also Merck & Co. v. Biocraft Labs. Inc., 874 F.2d 804, 809, 10 USPQ2d 1843, 1847-48 (Fed. Cir. 1989) (determination of suitable dosage amounts in diuretic compositions considered a matter of routine experimentation and therefore obvious). From the combined teaching of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary. 6. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 7. The claims 26-28, 33,34,38,39, 40,42 stand rejected on the grounds of nonstatutory double patenting of the claims of copending Applications No. 16378229 now allowed, for the same reasons set forth in the previous Office Action, mailed on 02/19/26. Applicant’s argument filed on 08/19/26 have been fully considered but have not been found convincing. Applicant asserts that claims of US Patent Application’229 teaches that the dose of administered expanded hematopoietic stem cells based on the weight of the patient. The instant claims recited administering of a fixed dose of hematopoietic stem cells. It is noted that the instant specification defined “fixed dose” as 50-400 x 106 cells ( see paragraph 0011 of the instant Specification in particular). Moreover, it noted that claims 4 and 5 of the US Patent Application’229 explicitly recited that the dose of administer cells is 75 and 260 x 106 cells Thus, it is the Examiner’s position that the claimed dose of administered “fixed dose” of hematopoietic stem cells is an obvious variation of the recited in claims 4 and 5 of US Patent Application’229 dose of administered hematopoietic stem cells. 8. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. 9. Claims 25-28,32-34,38,39,40,42,44 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, regards as the invention. Claim 25 is indefinite and ambiguous in the recitation of “administering of the second chemotherapy regimen followed by the administration of the fixed dose of the expanded stem cell product if desired or necessary”. The characteristics and metes and bounds of “if desired or necessary” are unclear and indefinite and Specification provide no guidance or clear definition of what applicant consider “desired or necessary”. It is suggested that said phrase be change to “ if a patient has not achieved a remission” for clarity and consistence with the disclosure of the specification. 10. No claim is allowed. 11. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 609(B)(2)(i). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. 12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskyi whose telephone number is 571/272-0840. The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gregory Emch can be reached on 571/ 2728149 /MICHAIL A BELYAVSKYI/Primary Examiner, Art Unit 1644
Read full office action

Prosecution Timeline

Nov 07, 2022
Application Filed
Feb 19, 2026
Non-Final Rejection mailed — §103, §112
Aug 19, 2026
Response Filed
Oct 27, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780888
NOVEL IMMUNOMODULATOR
4y 1m to grant Granted Nov 03, 2026
Patent 12780887
MUTATION COMPLEX INCLUDING GAIN-OF-FUNCTION MUTANT OF BMPR2 GENE, INDUCED PLURIPOTENT STEM CELLS AND MESENCHYMAL STEM CELLS DERIVED FROM MUTANT, AND USE THEREOF
3y 10m to grant Granted Nov 03, 2026
Patent 12766186
NERVE GROWTH FACTOR MUTANT
3y 8m to grant Granted Oct 20, 2026
Patent 12767715
SINGLE-DOMAIN ANTIBODY TARGETING PD-1, DERIVATIVE THEREOF AND USE THEREOF
3y 3m to grant Granted Oct 20, 2026
Patent 12760091
FIBRONECTIN TARGETING CHIMERIC ANTIGEN RECEPTORS (CARS)
4y 5m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
64%
Grant Probability
92%
With Interview (+28.0%)
3y 1m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1122 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month